Welsh Government has approved new advice from the All Wales Medicines Strategy Group (AWMSG) for three medicines.
- Hydroxycarbamide (Xromi®) was recommended to prevent the complications of blocked blood vessels caused by sickle cell disease only in patients over 2 years of age who are unable to swallow capsules.
- Belimumab (Benlysta®) was recommended in children and adolescents for the treatment of systemic lupus erythematosus, a disease in which the immune system (the body’s natural defences) attacks normal cells and tissues, causing inflammation and organ damage. Benlysta® is given to patients whose disease is still highly active despite standard treatment.
- Cariprazine (Reagila®) was not recommended to treat schizophrenia in adults.
AWTTC’s Patient Access to Medicines Service (PAMS) supports the AWMSG to assess and monitor new medicines in Wales.